

Booking Date	25/11/2024	Patient ID : 012411250196	Reported on 02/12/2024
Name	Lata Gupta	Age : 81 Years	Sex - Female
Ref By	Dr. Amish Vora		

DIAGNOSIS: Her2 IHC 2+ (Equivocal) Breast Cancer IDC


METHODOLOGY: Fluorescence *in situ* Hybridization (FISH)

PROBE NAME: HEALTHCARE HER2/CEP17 dual color probe.

FISH:

Total number of cells scored	100
Total number of HER2 signals	265
Total number of CEP17 signals	190
Average HER2 signals/cell	2.65
Computed Ratio	1.39

Negative



Cells showing HER2 signals (orange) and CEP17 signals (green).

CLINICAL INTERPRETATION:

1. Negative for HER2/neu amplification as per ASCO 2018 guidelines.
2. Her2:CEP17 ratio is <2 and Average Her2 signals <4 (Group 5).

RECOMMENDATION:

Please Note: 1. Evaluation of this specimen shows a normal hybridization pattern. These findings are indicative that the patient is not eligible for anti HER2 therapy (Trastuzumab). 2. Her2 gene amplification is seen 18 to 20% of invasive breast cancers. These tumours show increased overall survival rate with Her2 targeted therapy such as Trastuzumab. 3. It has been recognised as a poor prognosis indicator in early breast cancer. 4. In cases where tumor heterogeneity is present, analysis of HER2 FISH on additional blocks is recommended for conclusive result.